Meenhard Herlyn

List of Publications by Year
in descending order

186	26,954	9389 74	7703 152
papers	citations	h-index	g-index

383	383	383	43135
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	ERK hyperactivation serves as a unified mechanism of escape in intrinsic and acquired CDK4/6 inhibitor resistance in acral lentiginous melanoma. Oncogene, 2024, 43, 395-405.	5.9	2
2	Cell state dependent effects of Bmal1 on melanoma immunity and tumorigenicity. Nature Communications, 2024, 15, .	13.2	2
3	Nextflow pipeline for Visium and H&E data from patient-derived xenograft samples. Cell Reports Methods, 2024, 4, 100759.	3.0	0
4	Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations. Molecular Cancer Therapeutics, 2024, 23, 924-938.	3.7	0
5	A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis. Cancer Research, 2024, 84, 2060-2072.	0.9	0
6	Targeting UGCG Overcomes Resistance to Lysosomal Autophagy Inhibition. Cancer Discovery, 2023, 13, 454-473.	14.2	9
7	Induced pluripotent stem cells reprogramming overcomes technical limitations for highly pigmented adult melanocyte amplification and integration in <scp>3D</scp> skin model. Pigment Cell and Melanoma Research, 2023, 36, 232-245.	3.3	4
8	Targeting Fatty Acid Reprogramming Suppresses CARM1-expressing Ovarian Cancer. Cancer Research Communications, 2023, 3, 1067-1077.	1.8	5
9	Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors. Cancer Research, 2023, 83, 2790-2806.	0.9	8
10	Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant Melanoma. Molecular Cancer Therapeutics, 2023, 22, 1087-1099.	3.7	5
11	Melanoma-intrinsic NR2F6 activity regulates antitumor immunity. Science Advances, 2023, 9, .	10.9	2
12	Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells. Nature, 2023, 620, 651-659.	36.2	67
13	Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma. Nature Communications, 2022, 13, 1381.	13.2	41
14	Microbial communities of Auka hydrothermal sediments shed light on vent biogeography and the evolutionary history of thermophily. ISME Journal, 2022, 16, 1750-1764.	10.0	25
15	NUMB as a Therapeutic Target for Melanoma. Journal of Investigative Dermatology, 2022, 142, 1882-1892.e5.	0.7	5
16	PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery. NAR Cancer, 2022, 4, zcac014.	3.0	12
17	Persister state-directed transitioning and vulnerability in melanoma. Nature Communications, 2022, 13, .	13.2	22
18	Stromal changes in the aged lung induce an emergence from melanoma dormancy. Nature, 2022, 606, 396-405.	36.2	89

#	Article	IF	Citations
19	HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8+ T-cell infiltration into tumors. Nature Communications, 2022, 13, .	13.2	32
20	ClampFISH 2.0 enables rapid, scalable amplified RNA detection in situ. Nature Methods, 2022, 19, 1403-1410.	19.6	23
21	Extracellular Vesicles and Biomaterial Design: New Therapies for Cardiac Repair. Trends in Molecular Medicine, 2021, 27, 231-247.	7.1	32
22	ARID2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma. Journal of Investigative Dermatology, 2021, 141, 1564-1572.e4.	0.7	21
23	Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. Nature Communications, 2021, 12, 346.	13.2	128
24	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nature Genetics, 2021, 53, 86-99.	20.4	137
25	Inhibition of endothelin-B receptor signaling synergizes with MAPK pathway inhibitors in BRAF mutated melanoma. Oncogene, 2021, 40, 1659-1673.	5.9	8
26	The State of Melanoma: Emergent Challenges and Opportunities. Clinical Cancer Research, 2021, 27, 2678-2697.	7.2	58
27	Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling. Cancer Discovery, 2021, 11, 1716-1735.	14.2	39
28	Melanoma models for the next generation of therapies. Cancer Cell, 2021, 39, 610-631.	16.8	117
29	Evolution of delayed resistance to immunotherapy in a melanoma responder. Nature Medicine, 2021, 27, 985-992.	30.1	72
30	Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. Oncogene, 2021, 40, 5590-5599.	5.9	36
31	Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance. Cancer Research, 2021, 81, 5230-5241.	0.9	10
32	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. Nature Communications, 2021, 12, 5086.	13.2	66
33	A Modified Nucleoside 6-Thio-2â€²-Deoxyguanosine Exhibits Antitumor Activity in Gliomas. Clinical Cancer Research, 2021, 27, 6800-6814.	7.2	14
34	Production of Humanized Mouse via Thymic Renal Capsule Grafting, CD34⁺ Cells Injection, and Cytokine Delivery. Journal of Visualized Experiments, 2021, , .	0.3	0
35	TRIM15 and CYLD regulate ERK activation via lysine-63-linked polyubiquitination. Nature Cell Biology, 2021, 23, 978-991.	10.0	36
36	Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma. Nature Communications, 2021, 12, 6023.	13.2	27

#	Article	IF	Citations
37	Synergy of Bi₂O₃ and RuO₂ Nanocatalysts for Lowâ€Overpotential and Wide pHâ€Window Electrochemical Ammonia Synthesis. Chemistry - A European Journal, 2021, 27, 17395-17401.	3.9	8
38	Feasibility of Mechanical Properties of Lamina Hybrid Composite Ramie Fiber-Coconut Fiber-Fiberglass as an Alternative Hull Substitution of Material Structure Under 25M-V Type. E3S Web of Conferences, 2021, 328, 05006.	0.5	0
39	Costimulation of Î³Î´TCR and TLR7/8 promotes VÎ´2 T-cell antitumor activity by modulating mTOR pathway and APC function. , 2021, 9, e003339.		14
40	Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma. Molecular Cell, 2020, 77, 633-644.e5.	9.6	48
41	Nongenetic Mechanisms of Drug Resistance in Melanoma. Annual Review of Cancer Biology, 2020, 4, 315-330.	4.4	21
42	Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma. Cell Death and Disease, 2020, 11, 882.	6.4	11
43	Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma. Clinical Cancer Research, 2020, 26, 6039-6050.	7.2	26
44	Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines. Cancer Cell, 2020, 38, 829-843.e4.	16.8	41
45	SPANX Control of Lamin A/C Modulates Nuclear Architecture and Promotes Melanoma Growth. Molecular Cancer Research, 2020, 18, 1560-1573.	3.5	14
46	Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2. Cancer Discovery, 2020, 10, 1282-1295.	14.2	91
47	Pre-clinical modeling of cutaneous melanoma. Nature Communications, 2020, 11, 2858.	13.2	147
48	Targeting the cyclin-dependent kinase 5 in metastatic melanoma. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 8001-8012.	7.6	21
49	Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines. Cancer Research, 2020, 80, 4314-4323.	0.9	62
50	Prediagnostic plasma branched-chain amino acids and the risk of amyotrophic lateral sclerosis. Neurology, 2019, 92, e2081-e2088.	1.1	5
51	Polyunsaturated Fatty Acids from Astrocytes Activate PPARÎ³ Signaling in Cancer Cells to Promote Brain Metastasis. Cancer Discovery, 2019, 9, 1720-1735.	14.2	106
52	B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nature Communications, 2019, 10, 4186.	13.2	262
53	A Melanoma Patient-Derived Xenograft Model. Journal of Visualized Experiments, 2019, , .	0.3	11
54	BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells. Clinical Cancer Research, 2019, 25, 2783-2794.	7.2	26

#	Article	IF	Citations
55	Remodeling of the Collagen Matrix in Aging Skin Promotes Melanoma Metastasis and Affects Immune Cell Motility. Cancer Discovery, 2019, 9, 64-81.	14.2	283
56	Coâ€targeting <scp>BET</scp> and <scp>MEK</scp> as salvage therapy for <scp>MAPK</scp> and checkpoint inhibitorâ€resistant melanoma. EMBO Molecular Medicine, 2018, 10, .	7.3	83
57	Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Clinical Cancer Research, 2018, 24, 4771-4784.	7.2	31
58	MSX1-Induced Neural Crest-Like Reprogramming Promotes MelanomaÂProgression. Journal of Investigative Dermatology, 2018, 138, 141-149.	0.7	29
59	<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discovery, 2018, 8, 196-215.	14.2	429
60	Improvement of Current Transformer Accuracy by Digital Compensation Technique. , 2018, , .		1
61	<scp>GC</scp>â€<scp>MS</scp> metabolite profiling for specific detection of dwarf somaclonal variation in banana plants. Applications in Plant Sciences, 2018, 6, e01194.	2.2	12
62	Design of well-defined porous Ti2Nb10O29/C microspheres assembled from nanoparticles as anode materials for high-rate lithium ion batteries. Electrochimica Acta, 2018, 292, 759-768.	5.4	49
63	Frontiers in pigment cell and melanoma research. Pigment Cell and Melanoma Research, 2018, 31, 728-735.	3.3	10
64	A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell, 2018, 175, 984-997.e24.	27.8	973
65	Integrative Analyses of De Novo Mutations Provide Deeper Biological Insights into Autism Spectrum Disorder. Cell Reports, 2018, 22, 734-747.	6.3	143
66	LST1: A multifunctional gene encoded in the MHC class III region. Immunobiology, 2018, 223, 699-708.	1.9	8
67	Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nature Medicine, 2018, 24, 1545-1549.	30.1	521
68	Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature, 2018, 560, 382-386.	36.2	2,005
69	Swearing to be a good banker: Perceptions of the obligatory bankerâ€™s oath in the Netherlands. Journal of Banking Regulation, 2017, 18, 28-47.	2.2	10
70	Recent Advances in Melanoma and Melanocyte Biology. Journal of Investigative Dermatology, 2017, 137, 557-560.	0.7	12
71	Oncogenic RAS Regulates Long Noncoding RNA <i>Orilnc1</i> in Human Cancer. Cancer Research, 2017, 77, 3745-3757.	0.9	34
72	Snow and Rain Modify Neighbourhood Walkability for Older Adults. Canadian Journal on Aging, 2017, 36, 159-169.	1.4	36

#	Article	IF	Citations
73	Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature, 2017, 546, 431-435.	36.2	1,000
74	PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature, 2017, 550, 133-136.	36.2	146
75	Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nature Communications, 2017, 8, 607.	13.2	114
76	ATG5 Mediates a Positive Feedback Loop between Wnt Signaling and Autophagy in Melanoma. Cancer Research, 2017, 77, 5873-5885.	0.9	29
77	Enhancing CD8+ T Cell Fatty Acid Catabolism withinÂa Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. Cancer Cell, 2017, 32, 377-391.e9.	16.8	448
78	Polycyclic aromatic hydrocarbons in the water-SPM-sediment system from the middle reaches of Huai River, China: Distribution, partitioning, origin tracing and ecological risk assessment. Environmental Pollution, 2017, 230, 61-71.	7.7	62
79	Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. Cell Reports, 2017, 21, 1936-1952.	6.3	76
80	A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Cell Reports, 2017, 21, 1953-1967.	6.3	122
81	Measurement of detector-corrected observables sensitive to the anomalous production of events with jets and large missing transverse momentum in $$varvec{pp}$$ p p collisions at $$mathbf {sqrt{s}=13}$$ s = 13 ÂTeV using the ATLAS detector. European Physical Journal C, 2017, 77, 765.	4.0	23
82	Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget, 2017, 8, 25395-25417.	2.1	68
83	Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. Journal of Clinical Investigation, 2016, 126, 1834-1856.	8.2	229
84	Enhancing the evaluation of <scp>PI</scp>3K inhibitors through 3DÂmelanoma models. Pigment Cell and Melanoma Research, 2016, 29, 317-328.	3.3	13
85	The role of Oraiâ€"STIM calcium channels in melanocytes and melanoma. Journal of Physiology, 2016, 594, 2825-2835.	2.9	30
86	Randy Lomax, 1947-2016. Pigment Cell and Melanoma Research, 2016, 29, 605-606.	3.3	0
87	JARID1B Enables Transit between Distinct States of the Stem-like Cell Population in Oral Cancers. Cancer Research, 2016, 76, 5538-5549.	0.9	46
88	Crosstalk in skin: melanocytes, keratinocytes, stem cells, and melanoma. Journal of Cell Communication and Signaling, 2016, 10, 191-196.	3.5	52
89	Heterogeneity in Melanoma. Cancer Treatment and Research, 2016, 167, 1-15.	0.0	66
90	Personalized Preclinical Trials in BRAF Inhibitorâ€"Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clinical Cancer Research, 2016, 22, 1592-1602.	7.2	109

#	Article	IF	Citations
91	Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations. Experimental Dermatology, 2015, 24, 155-157.	2.9	43
92	Establishing Human Skin Grafts in Mice as Model for Melanoma Progression. Methods in Molecular Biology, 2015, , 1.	0.0	2
93	BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. Clinical Cancer Research, 2015, 21, 1652-1664.	7.2	112
94	UV-Induced Wnt7a in the Human Skin Microenvironment Specifies the Fate of Neural Crestâ€"Like Cells via Suppression of Notch. Journal of Investigative Dermatology, 2015, 135, 1521-1532.	0.7	18
95	<scp>W</scp>nt5<scp>A</scp> promotes an adaptive, senescentâ€like stress response, while continuing to drive invasion in melanoma cells. Pigment Cell and Melanoma Research, 2015, 28, 184-195.	3.3	78
96	Developmental pathways activated in melanocytes and melanoma. Archives of Biochemistry and Biophysics, 2014, 563, 13-21.	3.2	89
97	EGFR Inhibition Promotes an Aggressive Invasion Pattern Mediated by Mesenchymal-like Tumor Cells within Squamous Cell Carcinomas. Molecular Cancer Therapeutics, 2013, 12, 2176-2186.	3.7	23
98	The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells. Clinical Cancer Research, 2013, 19, 1784-1794.	7.2	99
99	Multi-channel search for squarks and gluinos in $sqrt{s}=7mbox{ TeV}$ pp collisions with the ATLAS detector at the LHC. European Physical Journal C, 2013, 73, 2362.	4.0	34
100	Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma. Cell Reports, 2013, 4, 1090-1099.	6.3	164
101	Suppression of Nucleotide Metabolism Underlies the Establishment and Maintenance of Oncogene-Induced Senescence. Cell Reports, 2013, 3, 1252-1265.	6.3	238
102	Relapse of melanoma after successful adoptive Tâ€cell therapy: escape through inflammationâ€induced phenotypic melanoma cell plasticity. Pigment Cell and Melanoma Research, 2013, 26, 2-3.	3.3	2
103	Isolation, Characterization, and Differentiation of Human Multipotent Dermal Stem Cells. Methods in Molecular Biology, 2013, 989, 235-246.	0.0	14
104	Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells. Cancer Cell, 2013, 23, 811-825.	16.8	572
105	Therapeutic Destruction of Insulin Receptor Substrates for Cancer Treatment. Cancer Research, 2013, 73, 4383-4394.	0.9	111
106	Comparative Secretome Analysis of Epithelial and Mesenchymal Subpopulations of Head and Neck Squamous Cell Carcinoma Identifies S100A4 as a Potential Therapeutic Target. Molecular and Cellular Proteomics, 2013, 12, 3778-3792.	3.9	34
107	Combination Therapy of Immunocytokines with Ipilimumab: A Cure for Melanoma?. Journal of Investigative Dermatology, 2013, 133, 595-596.	0.7	4
108	Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2. Cancer Discovery, 2013, 3, 1378-1393.	14.2	201

#	ARTICLE	IF	CITATIONS
109	There is a world beyond protein mutations: the role of nonâ€coding <scp>RNA</scp>s in melanomagenesis. Experimental Dermatology, 2013, 22, 303-306.	2.9	4
110	The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling. PLoS ONE, 2013, 8, e59588.	2.5	59
111	Targeting CD20 in Melanoma Patients at High Risk of Disease Recurrence. Molecular Therapy, 2012, 20, 1056-1062.	8.1	70
112	Isolation and Cultivation of Dermal Stem Cells that Differentiate into Functional Epidermal Melanocytes. Methods in Molecular Biology, 2012, 806, 15-29.	0.0	19
113	GSK3Î² Inhibition Blocks Melanoma Cell/Host Interactions by Downregulating N-Cadherin Expression and Decreasing FAK Phosphorylation. Journal of Investigative Dermatology, 2012, 132, 2818-2827.	0.7	37
114	Beyond ABC: Another Mechanism of Drug Resistance in Melanoma Side Population. Journal of Investigative Dermatology, 2012, 132, 2317-2319.	0.7	13
115	2F1558 The study of the dissociation and recovery reaction kinetics for photo-sensor protein UVR8(Photobiology:Vision & Photoreception II,Oral Presentation,The 50th Annual Meeting of the) Tj ETQq1 1 0.784314 rgBT /Ov	[illegible]	[illegible]
116	Fibroblasts Contribute to Melanoma Tumor Growth and Drug Resistance. Molecular Pharmaceutics, 2011, 8, 2039-2049.	4.7	112
117	Dermisâ€derived stem cells: a source of epidermal melanocytes and melanoma?. Pigment Cell and Melanoma Research, 2011, 24, 422-429.	3.3	59
118	The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression. Journal of Visualized Experiments, 2011, , .	0.3	69
119	Amodal completion in infants: Straight continuity versus symmetry1. Japanese Psychological Research, 2011, 53, 103-108.	1.3	1
120	Direct Reprogramming of Melanocytes to Neural Crest Stem-Like Cells by One Defined Factor. Stem Cells, 2011, 29, 1752-1762.	3.6	55
121	A NOTCH3-Mediated Squamous Cell Differentiation Program Limits Expansion of EMT-Competent Cells That Express the ZEB Transcription Factors. Cancer Research, 2011, 71, 6836-6847.	0.9	99
122	Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K. Cancer Cell, 2010, 18, 683-695.	16.8	1,150
123	Human dermal stem cells differentiate into functional epidermal melanocytes. Journal of Cell Science, 2010, 123, 853-860.	2.1	155
124	A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth. Cell, 2010, 141, 583-594.	27.8	1,072
125	PLX4032, a potent inhibitor of the Bâ€Raf V600E oncogene, selectively inhibits V600Eâ€positive melanomas. Pigment Cell and Melanoma Research, 2010, 23, 820-827.	3.3	146
126	Active Notch1 Confers a Transformed Phenotype to Primary Human Melanocytes. Cancer Research, 2009, 69, 5312-5320.	0.9	104

#	Article	IF	Citations
127	Multiresolution analysis of the two-dimensional free decaying turbulence in a pure electron plasma. New Journal of Physics, 2009, 11, 053006.	2.9	9
128	Integrating tumorâ€initiating cells into the paradigm for melanoma targeted therapy. International Journal of Cancer, 2009, 124, 1245-1250.	5.4	15
129	Driving in the melanoma landscape. Experimental Dermatology, 2009, 18, 506-508.	2.9	9
130	Embryonic Stem Cells as a Model for Studying Melanocyte Development. Methods in Molecular Biology, 2009, 584, 301-316.	0.0	3
131	Melanoma and the tumor microenvironment. Current Oncology Reports, 2008, 10, 439-446.	4.1	176
132	Matricellular Proteins Produced by Melanocytes and Melanomas: In Search for Functions. Cancer Microenvironment, 2008, 1, 93-102.	3.0	33
133	Melanoma Stem Cells: The Dark Seed of Melanoma. Journal of Clinical Oncology, 2008, 26, 2890-2894.	15.4	152
134	The Essential Role of Fibroblasts in Esophageal Squamous Cell Carcinomaâ€"Induced Angiogenesis. Gastroenterology, 2008, 134, 1981-1993.	1.4	123
135	Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3041-3046.	7.6	1,233
136	Role of stem cells in melanoma progression: hopes for a better treatment. Expert Review of Dermatology, 2007, 2, 191-201.	0.3	0
137	Targeting BRAF/MEK in melanoma: new hope or another false dawn?. Expert Review of Dermatology, 2007, 2, 179-190.	0.3	0
138	Farming cells to rebuild skin and melanoma. Cancer Biology and Therapy, 2007, 6, 467-471.	3.7	1
139	Microenvironmental influences in melanoma progression. Journal of Cellular Biochemistry, 2007, 101, 862-872.	2.6	79
140	Old disease, new culprit: Tumor stem cells in cancer. Journal of Cellular Physiology, 2007, 213, 603-609.	4.2	37
141	The many faces of Notch signaling in skin-derived cells. Pigment Cell & Melanoma Research, 2007, 20, 458-465.	3.2	65
142	Rewired ERK-JNK Signaling Pathways in Melanoma. Cancer Cell, 2007, 11, 447-460.	16.8	262
143	Roadmap for New Opportunities in Melanoma Research. Seminars in Oncology, 2007, 34, 566-576.	2.3	3
144	Isolation of a Novel Population of Multipotent Adult Stem Cells from Human Hair Follicles. American Journal of Pathology, 2006, 168, 1879-1888.	4.1	338

#	Article	IF	Citations
145	The Israel Lobby and U.S. Foreign Policy. Middle East Policy, 2006, 13, 29-87.	0.8	53
146	Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell & Melanoma Research, 2006, 19, 290-302.	3.2	494
147	Defining the Conditions for the Generation of Melanocytes from Human Embryonic Stem Cells. Stem Cells, 2006, 24, 1668-1677.	3.6	114
148	Molecular targets in melanoma: Strategies and challenges for diagnosis and therapy. International Journal of Cancer, 2006, 118, 523-526.	5.4	16
149	Inhibition of endothelial cell proliferation by Notch1 signaling is mediated by repressing MAPK and PI3K/Akt pathways and requires MAML1. FASEB Journal, 2006, 20, 1009-1011.	0.5	104
150	Notch1 Signaling Promotes Primary Melanoma Progression by Activating Mitogen-Activated Protein Kinase/Phosphatidylinositol 3-Kinase-Akt Pathways and Up-regulating N-Cadherin Expression. Cancer Research, 2006, 66, 4182-4190.	0.9	254
151	Pressure effects on the Î± and Î±â€² relaxations in polymethylphenylsiloxane. Journal of Chemical Physics, 2006, 124, 104901.	3.1	42
152	CCN3 controls 3D spatial localization of melanocytes in the human skin through DDR1. Journal of Cell Biology, 2006, 175, 563-569.	5.2	98
153	Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell & Melanoma Research, 2005, 18, 150-159.	3.2	309
154	Normal Human Melanocyte Homeostasis as a Paradigm for Understanding Melanoma. Journal of Investigative Dermatology Symposium Proceedings, 2005, 10, 153-163.	0.9	182
155	Selective evolutionary pressure from the tissue microenvironment drives tumor progression. Seminars in Cancer Biology, 2005, 15, 451-459.	9.8	53
156	Targeting the stromal fibroblasts: a novel approach to melanoma therapy. Expert Review of Anticancer Therapy, 2005, 5, 1069-1078.	2.6	20
157	Functional Erythropoietin Autocrine Loop in Melanoma. American Journal of Pathology, 2005, 166, 823-830.	4.1	75
158	Up-Regulated Expression of Zonula Occludens Protein-1 in Human Melanoma Associates with N-Cadherin and Contributes to Invasion and Adhesion. American Journal of Pathology, 2005, 166, 1541-1554.	4.1	143
159	Activation of Notch1 signaling is required for Â-catenin-mediated human primary melanoma progression. Journal of Clinical Investigation, 2005, 115, 3166-3176.	8.2	297
160	The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Frontiers in Bioscience - Landmark, 2005, 10, 2986.	3.1	230
161	Truncation of Activated Leukocyte Cell Adhesion Molecule: A Gateway to Melanoma Metastasis. Journal of Investigative Dermatology, 2004, 122, 1293-1301.	0.7	53
162	Reversal of melanocytic malignancy by keratinocytes is an E-cadherin-mediated process overriding Î²-catenin signaling. Experimental Cell Research, 2004, 297, 142-151.	2.6	31

#	ARTICLE	IF	CITATIONS
163	Particle aggregation monitoring by speckle size measurement; application to blood platelets aggregation. Optics Express, 2004, 12, 4596.	3.4	50
164	The Role of Altered Cellâ€“Cell Communication in Melanoma Progression. Journal of Molecular Histology, 2003, 35, 309-318.	2.2	136
165	Regulation of <i>Notch1</i> and <i>Dll4</i> by Vascular Endothelial Growth Factor in Arterial Endothelial Cells: Implications for Modulating Arteriogenesis and Angiogenesis. Molecular and Cellular Biology, 2003, 23, 14-25.	2.5	464
166	VEGFâ€A and Î± V Î² 3 integrin synergistically rescue angiogenesis via Nâ€Ras and PI3â€K signaling in human microvascular endothelial cells. FASEB Journal, 2003, 17, 1-21.	0.5	37
167	Epidermal Growth Factor Receptor Mediates Increased Cell Proliferation, Migration, and Aggregation in Esophageal Keratinocytes in Vitro and in Vivo. Journal of Biological Chemistry, 2003, 278, 1824-1830.	3.5	222
168	Fibroblastâ€dependent differentiation of human microvascular endothelial cells into capillaryâ€like, threeâ€dimensional networks. FASEB Journal, 2002, 16, 1316-1318.	0.5	132
169	Melanomaâ€“stroma interactions: structural and functional aspects. Lancet Oncology, The, 2002, 3, 35-43.	10.8	214
170	Melanoma development and progression: a conspiracy between tumor and host. Differentiation, 2002, 70, 522-536.	1.9	168
171	Mel-CAM-specific genetic suppressor elements inhibit melanoma growth and invasion through loss of gap junctional communication. Oncogene, 2001, 20, 4676-4684.	5.9	73
172	Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene, 2001, 20, 8125-8135.	5.9	175
173	Dynamics of intercellular communication during melanoma development. Trends in Molecular Medicine, 2000, 6, 163-169.	1.8	100
174	Human Melanoma Progression in Skin Reconstructs. American Journal of Pathology, 2000, 156, 193-200.	4.1	205
175	E-Cadherin Expression in Melanoma Cells Restores Keratinocyte-Mediated Growth Control and Down-Regulates Expression of Invasion-Related Adhesion Receptors. American Journal of Pathology, 2000, 156, 1515-1525.	4.1	326
176	Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes. Oncogene, 1999, 18, 6469-6476.	5.9	111
177	Study on â€œdouble dawnâ€• Science in China Series A: Mathematics, 1999, 42, 1224-1232.	0.5	2
178	Progression-related expression of Î²3 integrin in melanomas and nevi. Human Pathology, 1999, 30, 562-567.	2.3	118
179	Adenoviral Gene Transfer of Î²3 Integrin Subunit Induces Conversion from Radial to Vertical Growth Phase in Primary Human Melanoma. American Journal of Pathology, 1998, 153, 1435-1442.	4.1	201
180	Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Research, 1997, 7, S43.	1.2	96

#	Article	IF	Citations
181	Interactions of Melanocytes and Melanoma Cells With the Microenvironment. Pigment Cell & Melanoma Research, 1994, 7, 81-88.	3.2	44
182	In Vitro Growth Patterns of Normal Human Melanocytes and Melanocytes from Different Stages of Melanoma Progression. Journal of Immunotherapy, 1992, 12, 199-202.	2.5	41
183	Growth and Phenotoypic Characteristics of Human Nevus Cells in Culture. Journal of Investigative Dermatology, 1988, 90, 134-141.	0.7	50
184	Expression of the receptor for epidermal growth factor correlates with increased dosage of chromosome 7 in malignant melanoma. Somatic Cell and Molecular Genetics, 1985, 11, 297-302.	0.7	169
185	Efeitos da calagem nas caracterÃsticas quÃmicas do solo e na nutriÃ§Ã£o de soja em latossolo roxo distrÃ³fico de cerrado. Bragantia, 1976, 35, 273-278.	1.3	6
186	Analysis of the Events Leading to SV40-Induced Chromosome Replication and Mitosis in Primary Mouse Kidney Cell Cultures. Proceedings of the National Academy of Sciences of the United States of America, 1971, 68, 1208-1211.	7.6	24